This is a summary of the European public assessment report (EPAR) for NovoRapid. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use NovoRapid. For practical information about using NovoRapid, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
NovoRapid is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.
Therapeutic Area (MeSH)
ATC Code
A10AB05
ATC Item
N/A
Pharmacotherapeutic Group
Drugs used in diabetes
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| insulin aspart | N/A | insulin aspart |
EMA Name
NovoRapid
Medicine Name
NovoRapid
Aliases
N/ANo risk management plan link.
